v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2018
Jun. 30, 2018
Current assets:    
Cash $ 16,010 $ 15,934
Accounts receivable - trade 119 75
Prepaid expenses and other current assets 206 276
Total Current Assets 16,335 16,285
Fixed assets, net of accumulated depreciation 24,981 25,152
Intangible assets, net of accumulated amortization 1,554 1,620
Security deposit 26 26
Total Assets 42,896 43,083
Current liabilities:    
Accounts payable (related party of $185 and $189 as of September 30, 2018 and June 30, 2018, respectively) 692 790
Accrued expenses (related party of $812 and $789 as of September 30, 2018 and June 30, 2018, respectively) 1,125 1,048
Capital lease obligation – current portion 201 197
Deferred revenue 3,018 0
Total Current Liabilities 5,036 2,035
Capital lease obligation - net of current portion 24,832 24,884
Total Liabilities 29,868 26,919
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized; 18,336,792 and 16,040,126 shares issued and outstanding as of September 30, 2018 and June 30, 2018, respectively 18 16
Additional paid-in capital 105,670 104,408
Accumulated other comprehensive loss (31) (30)
Accumulated deficit (92,626) (88,228)
Total iBio, Inc. Stockholders' Equity 13,031 16,166
Noncontrolling interest (3) (2)
Total Equity 13,028 16,164
Total Liabilities and Equity 42,896 43,083
iBio CMO [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0

Source

v3.10.0.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Revenues $ 45 $ 122
Operating expenses:    
Research and development (related parties of $259 and $176), net of $0 and $44 in grant income 1,124 985
General and administrative (related parties of $261 and $206) 2,871 2,498
Total operating expenses 3,995 3,483
Operating loss (3,950) (3,361)
Other income (expense):    
Interest expense (related party of $476 and $480) (476) (480)
Interest income 21 5
Royalty income 6 9
Total other income (expense) (449) (466)
Consolidated net loss (4,399) (3,827)
Net loss attributable to noncontrolling interest 1 1
Net loss attributable to iBio, Inc. (4,398) (3,826)
Preferred stock dividends (66) (66)
Net loss available to iBio, Inc. (4,464) (3,892)
Comprehensive loss:    
Consolidated net loss (4,399) (3,827)
Other comprehensive loss - foreign currency translation adjustments (1) 0
Comprehensive loss $ (4,400) $ (3,827)
Loss per common share attributable to iBio, Inc. stockholders – basic and diluted $ (0.25) $ (0.42)
Weighted-average common shares outstanding – basic and diluted 17,894 9,185

Source

v3.10.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Consolidated net loss $ (4,399) $ (3,827)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:    
Share-based compensation 73 205
Amortization of intangible assets 83 85
Depreciation 360 338
Changes in operating assets and liabilities:    
Accounts receivable - trade (44) (85)
Work in process 0 26
Prepaid expenses and other current assets 70 77
Accounts payable (16) (78)
Accrued expenses 77 123
Deferred revenue 3,018 119
Net cash used in operating activities (778) (3,017)
Cash flows from investing activities:    
Additions to intangible assets (15) (15)
Purchases of fixed assets (274) (96)
Net cash used in investing activities (289) (111)
Cash flows from financing activities:    
Proceeds from sale of common stock 1,350 1,000
Costs to raise capital (159) 0
Payment of capital lease obligation (48) (44)
Net cash provided by financing activities 1,143 956
Net increase (decrease) in cash 76 (2,172)
Cash - beginning of period 15,934 8,088
Cash - end of period 16,010 5,916
Schedule of non-cash activities:    
Unpaid intangible assets included in accounts payable 3 7
Intangible assets included in accounts payable in prior period, paid in current period 2 11
Unpaid fixed assets included in accounts payable 0 9
Fixed assets included in accounts payable in prior period, paid in current period 85 87
Conversion of preferred stock into common stock 1 0
Supplemental cash flow information:    
Cash paid during the period for interest $ 477 $ 481

Source